Exercising its recently raised $20 million third funding round, Artemis Health has licensed non-invasive prenatal diagnostic technology from Stanford University. Initially, it licensed intellectual property from Massachusetts General Hospital and the Massachusetts Institute of Technology but has mostly been working in stealth mode since.

The acquisition is expected to help Artemis develop a fetal monitoring system superior to a typical amniocentesis. For example, the Stanford technology could help identify trisomy disorders like Down syndrome more easily. In the meantime, Artemis is continuing with internal trials of its diagnostic products and expects to launch its first within a year.

The last investment round, raised in September, came from Sutter Hill Ventures, Alloy Ventures and Mohr Davidow Ventures.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member